Roy Alvaro, Gaucher Laurent, Dupont Damien, Menotti Jean, Atallah Anthony, de la Fournière Benoit, Massoud Mona, Lina Bruno, Tirard-Collet Pauline, Wallon Martine
Department of Virology, Institute for Infectious Agents, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004 Lyon, France - National Centre for Epidemiology, Instituto de Salud Carlos III, Avenida de Monforte de Lemos 5, 28029 Madrid, Spain.
Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts, Av. de Champel 47, 1206 Geneva, Switzerland - Department of Maternal Fetal Medicine, University Hospital Femme Mère-Enfant, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France - Research on Healthcare Performance (RESHAPE), INSERM U1290, Claude Bernard University Lyon 1, 8 Avenue Rockefeller, 69373 Lyon, France.
Parasite. 2025;32:31. doi: 10.1051/parasite/2025023. Epub 2025 May 21.
The epidemiology of Toxoplasma infection is known to vary geographically, but is also likely to vary over time, under the influence of many contributing factors. Monitoring is particularly useful in the context of preventing congenital toxoplasmosis. We took advantage of the French prenatal prevention programme to retrospectively assess changes between 2017 and 2023 in seroprevalence and incidence rates of Toxoplasma infection in pregnant women and the incidence of congenital infections. We conducted a longitudinal retrospective study including all pregnancies with known Toxoplasma status followed up at Lyon's public maternity hospitals between 2017 and 2023 (71,922 pregnancies). We used a multivariable logistic regression model to identify factors (age-group, WHO region of origin, population density of the area of residence and parity) associated with seropositivity. The seroprevalence of toxoplasmosis decreased consistently from 26.4% in 2017 to 22.1% in 2023 (p = 0.003), while maternal infection incidence remained stable at 1.3/1,000 pregnancies at risk. Notably, the seroprevalence showed a linear increase with age from 18.9% in women aged 25-29 years to 38.0% in women aged ≥40 years (p < 0.001). The seroprevalence was lower in pregnant women living in rural areas [adjusted seroprevalence ratio (aPR) = 0.87, 95% CI: 0.82-0.92] and higher in multiparous women (aPR = 1.08, 95% CI: 1.04-1.12). This study confirms the ongoing decline in toxoplasmosis seroprevalence while seroconversions remained stable, indicating a need for more tests in seronegative women in the future. These findings highlight the need for ongoing monitoring and refinement of congenital toxoplasmosis prevention strategies in high-income countries.
已知弓形虫感染的流行病学情况在地理上存在差异,但在多种因素的影响下,其感染情况也可能随时间发生变化。在预防先天性弓形虫病方面,监测尤为有用。我们利用法国的产前预防计划,回顾性评估了2017年至2023年间孕妇弓形虫感染的血清阳性率和发病率以及先天性感染发病率的变化。我们进行了一项纵向回顾性研究,纳入了2017年至2023年间在里昂公立妇产医院接受随访且弓形虫感染状况已知的所有妊娠病例(共71,922例妊娠)。我们使用多变量逻辑回归模型来确定与血清阳性相关的因素(年龄组、世界卫生组织地区来源、居住地区人口密度和平产次数)。弓形虫病的血清阳性率从2017年的26.4%持续下降至2023年的22.1%(p = 0.003),而孕产妇感染发病率在有风险的妊娠中保持稳定,为1.3/1000。值得注意的是,血清阳性率随年龄呈线性增加,从25 - 29岁女性的18.9%增至40岁及以上女性的38.0%(p < 0.001)。居住在农村地区的孕妇血清阳性率较低[调整后血清阳性率比(aPR)= 0.87,95%置信区间:0.82 - 0.92],经产妇的血清阳性率较高(aPR = 1.08,95%置信区间:1.04 - 1.12)。本研究证实了弓形虫病血清阳性率持续下降,而血清转换率保持稳定,这表明未来需要对血清阴性女性进行更多检测。这些发现凸显了在高收入国家持续监测和完善先天性弓形虫病预防策略的必要性。